Skip to main content

Table 1 Patient characteristics and treatment with AIT

From: Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study

 

Concomitant AIT

No concomitant AIT

All patients treated

Patients, n

160

21

181

Age, years, mean ± SD

32.5 ± 13.9

28.2 ± 13.3

32.0 ± 13.9

Patients 5–11 years, n (%)

10 (6.3)

3 (14.3)

13 (7.2)

Patients 12–17 years, n (%)

13 (8.1)

1 (4.8)

14 (7.7)

Patients ≥18 years, n (%)

137 (85.6)

17 (81.0)

154 (85.1)

Gender, n (%)

 Male

68 (42.5)

11 (52.4)

79 (43.6)

 Female

92 (57.5)

10 (47.6)

102 (56.4)

Age at first diagnosis of allergy, years ± SD

26.8 ± 14.7

23.5 ± 13.5

26.5 ± 14.5

Major manifestations, n (%)

 Rhinitis

156 (97.5)

20 (95.2)

176 (97.2)

 Conjunctivitis

99 (61.9)

16 (76.2)

115 (63.5)

 Asthma

68 (42.5)

4 (19.0)

72 (39.8)

 Atopic dermatitis

14 (8.8)

3 (14.3)

17 (9.4)

Main allergies (multiple ratings), n (%)

 Grass pollen

160 (100.0)

21 (100.0)

181 (100.0)

 Tree pollen

101 (63.1)

7 (33.3)

108 (59.7)

 House dust mite

57 (35.6)

2 (9.5)

59 (32.6)

 Animal hair/dander

3 (1.9)

3 (1.7)

 Weed pollen

3 (1.9)

3 (1.7)

 Moulds

7 (4.4)

7 (3.9)

 Wasp venom

1 (0.6)

1 (0.6)

History of AIT, n (%)

18 (11.3)

7 (33.3)

25 (13.8)

Treatment with AIT, n (%)

 SQ® grass SLIT-tablet

160 (100.0)

21 (100.0)

181 (100.0)

 Concomitant SCIT

130 (81.3)

130 (71.8)

 Tree pollen

74 (46.3)

74 (40.9)

 House dust mite

40 (25.0)

40 (22.1)

 Other allergen

6 (3.8)a

6 (3.3)a

 Trees + mites

6 (3.8)

6 (3.3)

 Trees + other allergen

3 (1.9)b

3 (1.7)b

 Mites + dog

1 (0.6)

1 (0.6)

Concomitant SLIT

30 (18.8)

30 (16.6)

 Tree pollen

18 (11.3)

18 (9.9)

 House dust mite

8 (5.0)

8 (4.4)

 Other allergen

4 (2.5)c

4 (2.2)c

  1. aMoulds: n = 5; weed pollen: n = 1
  2. bCat: n = 1; weed pollen: n = 1; wasp venom: n = 1
  3. cCat: n = 1; moulds: n = 2; weed pollen: n = 1